Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug ATTO1310 tested for eczema and itch relief

NCT ID NCT06787586

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

This early-stage study tests a new drug called ATTO1310 to see if it is safe and how the body processes it. It includes healthy adults, people with atopic dermatitis (eczema), and those with long-term itching. Participants receive either the drug or a placebo and are monitored for side effects and symptom changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

108 people

The number who actually took part.

Started

Jan 2025

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Parts 1 \& 2 (Healthy Volunteers) Key Inclusion Criteria: * Any sex or gender who is 18 to 65 years old * Body weight of 50 to 125 kg and body mass index (BMI) between 18.5 and 35 kg/m2 * Considered in good general health based on medical history, physical exam, 12-lead ECG, screening clinical laboratory findings, and vital signs * Negative pregnancy test for subjects of child-bearing potential * Use of highly effective forms of birth control Part 3 (Subjects with Atopic Dermatitis) Inclusion Criteria: * Any sex or gender who is 18 to 65 years old * Body weight of 50 to 125 kg and BMI between 18.5 and 40 kg/m2 * Clinically confirmed diagnosis of active AD * At least a 1-year history of AD and had no significant flares in AD for at least 4 weeks before Screening * Baseline weekly mean of daily PP-NRS ≥ 7 at Day 1 * EASI score of ≥ 7 at Screening and Day 1 * vIGA-AD score of ≥ 3 at Screening and Day 1 * Use of topical bland emollient (moisturizer) once or twice daily for at least 5 of the 7 days immediately before Day 1 and agrees to continue using that same emollient at the same frequency throughout the study * Negative pregnancy test for subjects of child-bearing potential * Use of highly effective forms of birth control Part 4 (Subjects with Chronic Pruritus) Inclusion Criteria: * Any sex or gender who is 18 to 85 years old * Body weight of 50 to 125 kg, inclusive, and BMI between 18.5 and 40 kg/m2 * Has had chronic pruritus for at least 6 months and is unresponsive to at least a 2-week course of emollient use. * Chronic pruritus that affects at least 2 of the following body areas: legs, arms, or trunk * A single PP-NRS score of ≥ 5 in the 24-hour period prior to the Screening visit * Baseline weekly mean of daily PP-NRS ≥ 7 at Day 1 * Use of a stable dose of topical bland emollient (moisturizer) once or twice daily for at least 2 weeks before Day 1 and agrees to continue using that same emollient at the same frequency throughout the study * Negative pregnancy test for subjects of child-bearing potential * Use of highly effective forms of birth control Parts 1 \& 2 (Healthy Volunteers) Exclusion Criteria: * Any clinically significant underlying illness. * History of malignancy within 5 years of Screening, except adequately treated basal carcinoma or in situ carcinoma of the cervix. * History of major surgery within 8 weeks prior to Day 1 * History of asthma requiring regular use of a bronchodilator or a daily maintenance therapy * History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine) * Active hepatitis B virus (HBV) or hepatitis C virus (HCV) or is positive for HIV * Active or latent tuberculosis infection * Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent) per day * History of drug or alcohol abuse * Laboratory values outside of the normal range Exclusion Criteria for Part 3 (Subjects with Atopic Dermatitis): * Any clinically significant underlying illness * History of a clearly defined etiology for pruritus other than AD, including but not limited to urticaria, psoriasis, or other non-atopic dermatologic conditions, hepatic or renal disease, psychogenic pruritus, drug reaction, uncontrolled hyperthyroidism, and infection * History of malignancy within 5 years of Screening * History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study * History of asthma requiring regular use of a bronchodilator or a daily maintenance therapy * History of recurrent eczema herpeticum * History of known primary immunodeficiency, is considered immunocompromised, history of untreated latent tuberculosis infection, has been treated for active tuberculosis in the past year, or has been treated for a parasitic infection in the past 6 months * History of major depression * History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine) * Active HBV or HCV or is positive for HIV * Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent) per day * ECG with a QTcF \> 450 msec for males or \> 470 msec for females at Screening * History of drug or alcohol abuse * Subject has applied topical corticosteroid in the 14 days preceding Day 1 * Subject has used prohibited medications or therapies during the specified washout period before Day 1 (as defined in the protocol) * Laboratory values outside of the normal range Exclusion Criteria for Part 4 (Subjects with Chronic Pruritus): * Primary dermatologic diagnosis associated with pruritic skin lesions at the time of screening * Regional neuropathic disease associated with pruritus * Severe renal failure requiring dialysis * Untreated cholestatic liver disease * Liver function tests (bilirubin, AST, ALT, alkaline phosphatase) \>2.5 times above the upper limit of normal * History of infectious dermatoses * Suspected diagnosis of somatoform pruritus * Suspected diagnosis of drug-induced pruritus * History of malignancy within 5 years of Screening * History of unexplained fevers, night sweats, or unintentional weight loss * Major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study * History of asthma requiring regular use of a bronchodilator or a daily maintenance therapy * History of known primary immunodeficiency, is considered immunocompromised, untreated latent tuberculosis infection, has been treated for active tuberculosis in the past year, or has been treated for a parasitic infection in the past 6 months * History of attempted suicide * History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine) * Active HBV or HCV or is positive for HIV. * Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent) per day * ECG with a QTcF \> 450 msec for males or \> 470 msec for females at Screening * History of drug or alcohol abuse * Use of prohibited medications as defined in the Protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis (AD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Altasciences

    Montreal, Quebec, H3P 3P1, Canada

  • Attovia Clinical Site 102

    Plainfield, Indiana, 46168, United States

  • Attovia Clinical Site 103

    Encinitas, California, 92024, United States

  • Attovia Clinical Site 104

    Saint Joseph, Missouri, 64506, United States

  • Attovia Clinical Site 105

    Montreal, Quebec, H2X2V1, Canada

  • Attovia Clinical Site 106

    Reno, Nevada, 89509, United States

  • Attovia Clinical Site 107

    Sacramento, California, 95815, United States

  • Attovia Clinical Site 108

    San Antonio, Texas, 78213, United States

  • Attovia Clinical Site 109

    Coral Gables, Florida, 33134, United States

  • Attovia Clinical Site 110

    Fredericton, New Brunswick, E3B1G9, Canada

  • Attovia Clinical Site 111

    Newmarket, Ontario, L3Y 5G8, Canada

  • Attovia Clinical Site 112

    Peterborough, Ontario, K9J 5K2, Canada

  • Attovia Clinical Site 113

    Toronto, Ontario, M4W 2N4, Canada

  • Attovia Clinical Site 114

    New York, New York, 10029, United States

  • Attovia Clinical Site 116

    Rocklin, California, 95765, United States

  • Attovia Clinical Site 118

    Margate, Florida, 33063, United States

  • Attovia Clinical Site 119

    New York, New York, 10128, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.